Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1981 Mar;11(3):295–302. doi: 10.1111/j.1365-2125.1981.tb00537.x

Effect of naproxen on glucose metabolism and tolbutamide kinetics and dynamics in maturity onset diabetics.

B Whiting, R L Williams, M Lorenzi, J C Varady, D S Robins
PMCID: PMC1401608  PMID: 7213531

Abstract

1 The influence of the nonsteroidal anti-inflammatory drug naproxen on glucose metabolism and on tolbutamide pharmacokinetics and pharmacodynamics has been studied in ten maturity-onset diabetics. 2 Comparison of both plasma glucose decay curves and insulin responses during an intravenous glucose tolerance test before and after eight 12 hourly doses of naproxen revealed that naproxen had no significant influence on fasting glucose levels or on rates of glucose elimination. 3 When the subjects were given a combination of naproxen and tolbutamide for 3 days naproxen had no influence on tolbutamide absorption, protein binding, disposition or pharmacological effect. 4 Treatment with tolbutamide in maturity-onset diabetics need not be modified if concurrent administration of naproxen is contemplated.

Full text

PDF
295

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aggeler P. M., O'Reilly R. A., Leong L., Kowitz P. E. Potentiation of anticoagulant effect of warfarin by phenylbutazone. N Engl J Med. 1967 Mar 2;276(9):496–501. doi: 10.1056/NEJM196703022760904. [DOI] [PubMed] [Google Scholar]
  2. Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Naproxen up to date: a review of its pharmacological properties and therapeutic efficacy and use in rheumatic diseases and pain states. Drugs. 1979 Oct;18(4):241–277. doi: 10.2165/00003495-197918040-00001. [DOI] [PubMed] [Google Scholar]
  3. Chen M., Robertson R. P. Restoration of the acute insulin response by sodium salicylate. A glucose dose-related phenomenon. Diabetes. 1978 Jul;27(7):750–756. doi: 10.2337/diab.27.7.750. [DOI] [PubMed] [Google Scholar]
  4. GRODSKY G. M., FORSHAM P. H. An immunochemical assay of total extractable insulin in man. J Clin Invest. 1960 Jul;39:1070–1079. doi: 10.1172/JCI104122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Giugliano D., Torella R., Siniscalchi N., Improta L., D'Onofrio F. The effect of acetylsalicylic acid on insulin response to glucose and arginine in normal man. Diabetologia. 1978 Jun;14(6):359–362. doi: 10.1007/BF01228129. [DOI] [PubMed] [Google Scholar]
  6. Jain A. K., Ryan J. R., McMahon F. G. Potentiation of hypoglycemic effect of sulfonylureas by halofenate. N Engl J Med. 1975 Dec 18;293(25):1283–1286. doi: 10.1056/NEJM197512182932503. [DOI] [PubMed] [Google Scholar]
  7. Lewis R. J., Trager W. F., Chan K. K., Breckenridge A., Orme M., Roland M., Schary W. Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest. 1974 Jun;53(6):1607–1617. doi: 10.1172/JCI107711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Matin S. B., Rowland M. Determination of tolbutamide and chlorpropamide in biological fluids. J Pharm Pharmacol. 1973 Feb;25(2):186–188. doi: 10.1111/j.2042-7158.1973.tb10620.x. [DOI] [PubMed] [Google Scholar]
  9. Micossi P., Pontiroli A. E., Baron S. H., Tamayo R. C., Lengel F., Bevilacqua M., Raggi U., Norbiato G., Foà P. P. Aspirin stimulates insulin and glucagon secretion and increases glucose tolerance in normal and diabetic subjects. Diabetes. 1978 Dec;27(12):1196–1204. doi: 10.2337/diab.27.12.1196. [DOI] [PubMed] [Google Scholar]
  10. Pond S. M., Birkett D. J., Wade D. N. Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):573–579. doi: 10.1002/cpt1977225part1573. [DOI] [PubMed] [Google Scholar]
  11. Robertson R. P., Chen M. A role for prostaglandin E in defective insulin secretion and carbohydrate intolerance in diabetes mellitus. J Clin Invest. 1977 Sep;60(3):747–753. doi: 10.1172/JCI108827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Robertson R. P., Gavareski D. J., Porte D., Jr, Bierman E. L. Inhibition of in vivo insulin secretion by prostaglandin E1. J Clin Invest. 1974 Aug;54(2):310–315. doi: 10.1172/JCI107766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Robertson R. P., Metz S. A. Sounding board. Prostaglandins, the glucoreceptor, and diabetes. N Engl J Med. 1979 Dec 27;301(26):1446–1447. doi: 10.1056/NEJM197912273012612. [DOI] [PubMed] [Google Scholar]
  14. Schary W. L., Lewis R. J., Rowland M. Warfarin-phenylbutazone interaction in man: a long term multiple dose study. Res Commun Chem Pathol Pharmacol. 1975 Apr;10(4):663–672. [PubMed] [Google Scholar]
  15. Slattery J. T., Levy G., Jain A., McMahon F. G. Effect of naproxen on the kinetics of elimination and anticoagulant activity of a single dose or warfarin. Clin Pharmacol Ther. 1979 Jan;25(1):51–60. doi: 10.1002/cpt197925151. [DOI] [PubMed] [Google Scholar]
  16. Solomon H. M., Schrogie J. J. The effect of various drugs on the binding of warfarin-14C to human albumin. Biochem Pharmacol. 1967 Jul 7;16(7):1219–1226. doi: 10.1016/0006-2952(67)90153-0. [DOI] [PubMed] [Google Scholar]
  17. Upton R. A., Buskin J. N., Guentert T. W., Williams R. L., Riegelman S. Convenient and sensitive high-performance liquid chromatography assay for ketoprofen, naproxen and other allied drugs in plasma or urine. J Chromatogr. 1980 Mar 21;190(1):119–128. doi: 10.1016/s0021-9673(00)85518-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES